Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Sep 5:4:267.
doi: 10.3389/fmicb.2013.00267.

Animal models for Ebola and Marburg virus infections

Affiliations
Review

Animal models for Ebola and Marburg virus infections

Eri Nakayama et al. Front Microbiol. .

Abstract

Ebola and Marburg hemorrhagic fevers (EHF and MHF) are caused by the Filoviridae family, Ebolavirus and Marburgvirus (ebolavirus and marburgvirus), respectively. These severe diseases have high mortality rates in humans. Although EHF and MHF are endemic to sub-Saharan Africa. A novel filovirus, Lloviu virus, which is genetically distinct from ebolavirus and marburgvirus, was recently discovered in Spain where filoviral hemorrhagic fever had never been reported. The virulence of this virus has not been determined. Ebolavirus and marburgvirus are classified as biosafety level-4 (BSL-4) pathogens and Category A agents, for which the US government requires preparedness in case of bioterrorism. Therefore, preventive measures against these viral hemorrhagic fevers should be prepared, not only in disease-endemic regions, but also in disease-free countries. Diagnostics, vaccines, and therapeutics need to be developed, and therefore the establishment of animal models for EHF and MHF is invaluable. Several animal models have been developed for EHF and MHF using non-human primates (NHPs) and rodents, which are crucial to understand pathophysiology and to develop diagnostics, vaccines, and therapeutics. Rhesus and cynomolgus macaques are representative models of filovirus infection as they exhibit remarkably similar symptoms to those observed in humans. However, the NHP models have practical and ethical problems that limit their experimental use. Furthermore, there are no inbred and genetically manipulated strains of NHP. Rodent models such as mouse, guinea pig, and hamster, have also been developed. However, these rodent models require adaptation of the virus to produce lethal disease and do not mirror all symptoms of human filovirus infection. This review article provides an outline of the clinical features of EHF and MHF in animals, including humans, and discusses how the animal models have been developed to study pathophysiology, vaccines, and therapeutics.

Keywords: Ebola virus; Marburg virus; animal models; filovirus; viral hemorrhagic fever.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Phylogenetic analysis of filovirus based on nucleotide sequence. The phylogenetic tree based on complete viral genome sequences was constructed by using the neighbor-joining method. Numbers at branch points indicate bootstrap values (1000 replicates). The GenBank accession numbers of Tai Forest virus (TAFV), Bundibugyo virus (BDBV), Ebola virus (EBOV), Reston virus (RESTV), Sudan virus (SUDV), Lloviu virus (LLOV), Marburg virus (MARV), and Ravn virus (RAVV) are FJ217162, FJ217161, AF086833, AB050936, AY729654, JF828358, DQ217792, and EF446131, respectively.

References

    1. Abbink P., Lemckert A. A., Ewald B. A., Lynch D. M., Denholtz M., Smits S., et al. (2007). Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81, 4654–4663 10.1128/JVI.02696-06 - DOI - PMC - PubMed
    1. Alves D. A., Glynn A. R., Steele K. E., Lackemeyer M. G., Garza N. L., Buck J. G., et al. (2010). Aerosol exposure to the angola strain of marburg virus causes lethal viral hemorrhagic Fever in cynomolgus macaques. Vet. Pathol. 47, 831–851 10.1177/0300985810378597 - DOI - PubMed
    1. Aman M. J., Kinch M. S., Warfield K., Warren T., Yunus A., Enterlein S., et al. (2009). Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res. 83, 245–251 10.1016/j.antiviral.2009.06.001 - DOI - PubMed
    1. Arai A., Hirano H., Ueta Y., Hamada T., Mita T., Shirahata A. (2000). Detection of mononuclear cells as the source of the increased tissue factor mRNA in the liver from lipopolysaccharide-treated rats. Thromb. Res. 97, 153–162 10.1016/S0049-3848(99)00147-4 - DOI - PubMed
    1. Baize S., Leroy E. M., Georges A. J., Georges-Courbot M. C., Capron M., Bedjabaga I., et al. (2002). Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol. 128, 163–168 10.1046/j.1365-2249.2002.01800.x - DOI - PMC - PubMed